Publications

Journal Article Ppublish 159 citations
Electronic publication date
February 28, 2001

View on Pubmed.gov 11121904 | View on doi.org 10.1046/j.1365-...

A pilot study of N-acetyl glucosamine, a nutritional substrate for glycosaminoglycan synthesis, in paediatric chronic inflammatory bowel disease.

Search for publications in this journal Aliment Pharmacol Ther - 14(12):1567-79

Abstract

BACKGROUND

The breakdown of glycosaminoglycans is an important consequence of inflammation at mucosal surfaces, and inhibition of metalloprotease activity may be effective in treating chronic inflammation.

AIM

To report an alternative approach, using the nutriceutical agent N-acetyl glucosamine (GlcNAc), an amino-sugar directly incorporated into glycosaminoglycans and glycoproteins, as a substrate for tissue repair mechanisms.

METHODS

GlcNAc (total daily dose 3-6 g) was administered orally as adjunct therapy to 12 children with severe treatment-resistant inflammatory bowel disease (10 Crohn's disease, 2 ulcerative colitis). Seven of these children suffered from symptomatic strictures. In addition, similar doses were administered rectally as sole therapy in nine children with distal ulcerative colitis or proctitis resistant to steroids and antibiotics. Where pre- and post-treatment biopsies were available (nine cases), histochemical assessment of epithelial and matrix glycosaminoglycans and GlcNAc residues was made.

FINDINGS

Eight of the children given oral GlcNAc showed clear improvement, while four required resection. Of the children with symptomatic Crohn's stricture, only 3 of 7 have required surgery over a mean follow-up of > 2.5 years, and endoscopic or radiological improvement was detected in the others. Rectal administration induced remission in two cases, clear improvement in three and no effect in two. In all cases biopsied there was evidence of histological improvement, and a significant increase in epithelial and lamina propria glycosaminoglycans and intracellular GlcNAc.

CONCLUSIONS

GlcNAc shows promise as an inexpensive and nontoxic treatment in chronic inflammatory bowel disease, with a mode of action which is distinct from conventional treatments. It may have the potential to be helpful in stricturing disease. However, controlled trials and an assessment of enteric-release preparations are required to confirm its efficacy and establish indications for use.

References

No references provided.

Cited by 159 citations (total)

Journal Article Research Support, Non-U.S. Gov't

Integrated regulatory responses of fimB to N-acetylneuraminic (sialic) acid and GlcNAc in Escherichia coli K-12.

Electronic publication date December 28, 2004

Search for publications in this journal Proc Natl Acad Sci U S A

Baljinder K Sohanpal [...] Ian C Blomfield et al.

Bacterial-host attachment by means of bacterial adhesins is a key step in host colonization. Phase variation (reversible on-off switching) of...

Journal Article Research Support, Non-U.S. Gov't

N-acetyl glucosamine obtained from chitin by chitin degrading factors in Chitinbacter tainanesis.

Electronic publication date May 5, 2011

Search for publications in this journal Int J Mol Sci

Jeen-Kuan Chen [...] Chao-Lin Liu et al.

A novel chitin-degrading aerobe, Chitinibacter tainanensis, was isolated from a soil sample from southern Taiwan, and was proved to produce...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances